Kite Pharma, founded in 2009, is a clinical stage biopharmaceutical company focused on the development and comercialization of novel cancer immunotherapy products designed to harness the power of a patients own immune system to eradicate cancer cells.
Our goal is to be a leader in immunotherapy in multiple cancer indications. To achieve this, we are developing a pipeline of product candidates for the treatment of advanced solid and hematological malignancies using our therapeutic platform – engineered Autologous Cell Therapy (eACT™) – in which a patient’s own T cells, or white blood cells, are engineered to recognize and destroy their cancer. The patient’s immune system, particularly T cells, plays a critical role in identifying and killing cancer cells. Our eACT™ technology involves the genetic engineering of T cells to express either chimeric antigen receptors (CARs), or T cell receptors (TCRs). Our technology has been developed in part through our collaboration with the National Cancer Institute, Surgery Branch through a cooperative research and development agreement (CRADA).
Kite Pharma is advancing a pipeline of proprietary eACT™-based product candidates to create personalized therapies targeting a broad range of indications in cancer.